Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery
NCT07011147
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this randomized controlled trial is to compare the efficacy and safety of the iLet Bionic Pancreas (BP) System in adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes) compared to standard of care when ordered by primary care providers. The main question it aims to answer is: Can the iLet BP by deployed in primary care settings to adults with insulin-treated diabetes (type 1 diabetes or type 2 diabetes)? Researchers will compare 13-weeks of iLet BP use to routine care to see if iLet BP use has a greater reduction in HbA1c compared to13-weeks of routine care.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 1 Diabetes (T1D)
- Type 2 Diabetes
- Diabetes, Autoimmune
- Diabetes Mellitus
- Diabetes Mellitus Type 2
- Diabetes Mellitus, Type I
- Diabetes, Type II
- Diabetes
- Diabetes Mellitus, Insulin-Dependent
- Diabetes Mellitus Type II
- Diabetes Type 2 on Insulin
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Colorado, Denver
- Last updated on ClinicalTrials.gov
- June 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado Anschutz Medical Campus · Aurora, CO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.